Welcome to the Hiebert Laboratory
The study of acute leukemia yielded the first demonstration of a genetic alteration in human cancer, the identification of the first oncogene in humans, the first demonstration of impairment of apoptosis in tumorigenesis, the first description of chromosomal translocations resulting in fusion oncogenes, and the first application of targeted therapeutics in cancer.
In the Hiebert Lab, we are utilizing cutting edge technology (PRO-seq, dTAG, endogenous AP-MS, etc.) to study the transcriptional control of Acute Myeloid Leukemia (AML) and Diffuse Large B-Cell Lymphoma (DLBCL). With these new technologies and our expertise in hematopoiesis, we’re answering decades-old questions surrounding the basic biology of leukemogenesis and lymphomagenesis.
The lab is part of the Genome Maintenance Program within the Vanderbilt-Ingram Cancer Center, the Department of Biochemistry and the Vanderbilt Institute of Chemical Biology at the Vanderbilt University School of Medicine.